pSivida Corp. (NASDAQ:PSDV)‘s current stock price of $1.75 indicates a change of -15.87% from the previous session.
While the equity is currently trading close to $1.75, analysts on the average expect the stock trading around of $9.38 in the next 12 months.
Analyzing historical, you can note that the stock’s high over the last 12-months is $-58.82% and its lowest over the comparable period is $16.67%.
Let’s look into the stock charts:
The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Average. The market is approaching oversold territory. Be watchful of a trend reversal.
The average closing price of the equity for the last 20 days, or termed as 20-day simple moving average, is $-19.24%. For the previous 50 days and 200 days, the equity?s closing has averaged $-9.35% and $-17.79%, respectively.
How volatile is pSivida Corp.’s stock paralleled to the market? The stock’s beta is 1.28. Beta is a degree of stock volatility. So, a beta less than one exhibits that an equity is less volatile compared to the market and a beta that is greater than one compared to stock is increasingly volatile than the market.
Pertaining to volatility measurement, we can note that pSivida Corp.?s weekly volatility is 6.45%, while its monthly volatility is 6.26%.
Furthermore, the stock’s ATR (average true range) is 0.14. ATR calculates the degree of a stock’s price volatility.
Coming to stock performance, find the scorecard of pSivida Corp.’s stock price action for the previous one week going back to the preceding one year. The stock has moved -18.22%% in the last, while it has moved -15.87% in the past one month.
The stock has moved 4.48% over the past 3-months of one quarter. So far in this year, the stock has moved 2.34%, compared with a movement of -48.98% in the last 12-months.
Other than equity performance, where does pSivida Corp. stand financially? The firm closed the previous quarter with cash balance of 12.87M%, bringing its total assets at the close of the quarter to $17.51M.
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced the Company’s second Phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved the trial’s primary endpoint. The study involved 153 patients and the primary endpoint was prevention of recurrence of posterior uveitis at six months with patients continuing to be followed for 36 months. Durasert three-year insert demonstrated a significant reduction in the recurrence of posterior segment uveitis through six months; 21.8% of Durasert-treated patients had a recurrence compared to 53.8% of patients in the sham group (p<0.001).